[Double-blind group comparison of topical meclocycline, erythromycin and placebo in the treatment of papulo-pustulosa acne]. / Doppelblinder Gruppenvergleich von topischem Meclocyclin, Erythromycin und Placebo in der Behandlung der Akne papulo-pustulosa.

Ten institutions participated in a controlled clinical trial in order to evaluate the efficacy of topical meclocycline and erythromycin in comparison to placebo with regard to papulopustular acne. Both drugs had been incorporated in the same galenic formulation that served as placebo. The vehicle employed in this study guaranteed equally favorable drug relies for both preparations. At the end of the trial, 419 patients could be evaluated for efficacy. As impartial criterion for evaluation, the number of inflammatory lesions on the right side of the face was counted before and after three months of treatment. In addition, we recorded the patients' and physicians' overall judgment at the end of the study. As compared with placebo, meclocycline as well as erythromycin brought about statistically significant improvement already after two months of treatment. After three months, the results were statistically very highly significant (p less than 0.001). At any time of the study, there could not be demonstrated any difference between the two groups treated with meclocycline and erythromycin.

[Radioimmuno assay of the sulfonylurea AR-DF 26(author's transl)]. / Radioimmunologische Bestimmung des Sulfonylharnstoffes AR-DF 26

A radioimmunological method was developed for 1-cyclohexyl-3-[p-(beta-4,4-dimethyl-7-methoxy-1,3-(2H,4H)-isoquinolinedion-2-yl)phenethyl]-sulfonylurea (AR-DF 26, gliquidone, Glurenorm) estimations in plasma. The antisera were obtained by immunization of rabbits with AR-DF 26-bovine serum albumin (BSA) conjugate. The estimation is based on the competitive displacement in plasma samples of known amounts of labelled AR-DF 26, bound to a specific antibody by unknown amounts of unlabelled AR-DF 26. Concentrations of as low as 1 ng of AR-DF 26 per sample can be measured by this method. The investigations into the specificity of this reaction have shown that the antiserum is extremely specific for AR-DF 26. There is good reproducibility of the results and no differences could be found by variance analysis between different measurements of the same AR-DF 26 concentration. Since more than 70% of the plasma concentration correspond to unchanged AR-DF 26 for a longer period after application, the results of this AR-DF 26-radioimmuno assay is only minimally altered by its metabolites.